SDC2 and gastric cancer: In contrast, we observed that the GC patients whose tumors expressed higher levels of SDC2 (mRNA level > 8.12) had significantly shorter overall survival and recurrence-free survival compared to GC patients whose tumors had lower SDC2 expression (Fig. 1A).